Cell Therapy CDMOs — Ranked by Signal Score · 2026

· updated as new inspection, certificate, and trial data enters the platform

Cell Therapy manufacturers on CDMO Signal: 63 listed. 9 are fully evidenced (all four Signal Score pillars and at least one ClinicalTrials.gov match). The highest Signal Scores in that fully evidenced set are Bristol Myers Squibb (CGT Mfg) (in-house manufacturer, Signal Score 87), City of Hope (T Cell Manufacturing) (academic or national centre, Signal Score 84) and Takeda (also makes its own products, Signal Score 83.4). Outside that set, higher Signal Scores on this list include Charles River Laboratories (Signal Score 86.3). A higher score there is not a fully evidenced record. The score does not measure autologous versus allogeneic experience, closed-system processing, or chain of identity. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology.

Cell Therapy CDMOs with the most regulatory evidence on file

AGC Biologics
79.9
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
4 FDA inspections · 27 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-29 · NAI
See the evidence →
Takeda
83.4
Boston, MA · Zurich, CH
4 FDA inspections · 20 EMA/MHRA GMP certs
Last FDA inspection: 2026-04-10 · NAI
See the evidence →
Charles River Laboratories
86.3
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
9 FDA inspections · 11 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-01 · NAI
See the evidence →
Lonza
72.8
Basel, Switzerland
11 FDA inspections · 8 EMA/MHRA GMP certs
Last FDA inspection: 2025-09-29 · VAI
See the evidence →
Bristol Myers Squibb (CGT Mfg)
87.0
Bothell, WA · Warren, NJ
8 FDA inspections · 2 EMA/MHRA GMP certs
Last FDA inspection: 2026-04-28 · NAI
See the evidence →
63
CDMOs tracked
63
Fully scored
17
With FDA records
70
FDA inspections
118
EMA/MHRA GMP certs
6
Warning letters

Cell therapy CDMOs manufacture living products — CAR-T, TCR, NK, and stem-cell therapies — where the process is the product. Autologous programs add patient-scheduling and chain-of-identity demands that allogeneic, batch-based programs avoid.

The right cell therapy CDMO depends on autologous vs allogeneic experience, vector sourcing, closed-system processing, and cold-chain logistics. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 32 NAI (no action), 35 VAI (voluntary action), 3 OAI (official action). Leading inspection & GMP sites: United States (46), Denmark (23), Germany (19), Ireland (17), UNITED KINGDOM (15).

Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing all operator types.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
BMS
Bothell, WA · Warren, NJ
Fully evidenced
In-house manufacturer
87.0 97.2 8 insp · 2 GMP 2026-04-28 · NAI — 585 programs
2
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
86.3 99.2 9 insp · 11 GMP 2026-05-01 · NAI Limited —
3
COH
Duarte, CA
Fully evidenced
Academic / national centre
84.0 97.3 3 insp · 0 GMP 2025-08-20 · VAI — 213 programs
4
TK
Boston, MA · Zurich, CH
Fully evidenced
Also makes its own products
83.4 100.0 4 insp · 20 GMP 2026-04-10 · NAI — 100 programs
5
MN
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
83.1 99.2 3 insp · 4 GMP 2025-11-25 · NAI Limited —
6
WB2
Shanghai, CN · Wuxi, CN
82.7 99.6 1 insp · 4 GMP 2026-07-03 · VAI — —
7
MK
Darmstadt, DE · St. Louis, MO
Hiring · 8 open roles
Fully evidenced
Also makes its own products
81.9 98.8 2 insp · 2 GMP 2025-04-28 · VAI — 22 programs
8
SC
Prague, Czech Republic
81.6 100.0 0 insp · 5 GMP None on file — —
9
EF
Planegg, DE · San Diego, CA
81.6 100.0 7 insp · 0 GMP 2026-05-15 · NAI — —
10
CF
Les Ulis, FR
80.3 100.0 0 insp · 4 GMP None on file — —
11
SG
Bengaluru, India
Hiring · 4 open roles
80.3 100.0 3 insp · 0 GMP 2025-02-20 · NAI — —
12
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
79.9 99.8 4 insp · 27 GMP 2026-05-29 · NAI Available 2 programs
13
SK
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
79.5 100.0 — None on file Available —
14
RC
Edinburgh, UK · Hopkinton, MA
Hiring · 8 open roles
79.3 96.8 1 insp · 1 GMP 2025-01-21 · VAI Available —
15
NG
Leiden, NL
78.1 100.0 0 insp · 1 GMP None on file — —
16
CE
Basel, Switzerland
Hiring · 4 open roles
78.1 100.0 0 insp · 1 GMP None on file — —
17
XP
Bristol, United Kingdom
78.1 100.0 0 insp · 1 GMP None on file — —
18
GP
San Diego, CA
78.1 100.0 0 insp · 1 GMP None on file — —
19
CS
Los Angeles, CA
Hiring · 1 open role
Fully evidenced
Academic / national centre
77.3 92.9 2 insp · 0 GMP 2025-03-14 · NAI — 34 programs
20
SY
Stirling, United Kingdom
76.8 100.0 1 insp · 8 GMP 2025-01-31 · NAI — —
21
CY
Toulouse, FR
76.8 100.0 0 insp · 2 GMP None on file — —
22
CN
Luxembourg, LU
76.8 100.0 0 insp · 1 GMP None on file — —
23
HH
London, United Kingdom
76.8 100.0 0 insp · 4 GMP None on file — —
24
FH
Seattle, WA
Academic / national centre
76.3 — — None on file — 454 programs
25
BC
Bengaluru, India
Hiring · 48 open roles
75.7 93.1 7 insp · 2 GMP 2025-09-03 · VAI — —
26
BY
Berkeley, CA
In-house manufacturer
75.2 — — None on file — 126 programs
27
NR
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Hiring · 100+ open roles
Fully evidenced
73.6 95.6 1 insp · 0 GMP 2025-01-21 · VAI Available 9 programs
28
DH
Washington, DC
Platform provider
73.0 — — None on file — —
29
MB
Bergisch Gladbach, Germany
Fully evidenced
73.0 100.0 0 insp · 2 GMP None on file — 8 programs
30
Basel, Switzerland
Hiring · 100+ open roles
Fully evidenced
72.8 86.6 11 insp · 8 GMP 2025-09-29 · VAI — 1 program
31
BB
Durham, NC
In-house manufacturer
70.5 — — None on file — —
32
IO
Philadelphia, PA
Hiring · 9 open roles
In-house manufacturer
65.9 — — None on file — 31 programs
33
CG
Marlborough, MA · Uppsala, SE
Platform provider
65.5 — — None on file — —
34
Piscataway, NJ / Nanjing, China
64.0 — — None on file — —
35
VE
Rockville, MD · Memphis, TN · Keele, United Kingdom
64.0 — — None on file — —
36
PBI
Pennington, NJ · Nanjing, CN
64.0 — — None on file — —
37
CT
Houston, TX
Academic / national centre
63.0 — — None on file — —
38
RA
Stockholm, Sweden
63.0 — — None on file — —
39
HG
Yokohama, Japan
Also makes its own products
63.0 — — None on file — —
40
SM
Tokyo, JP
Also makes its own products
63.0 — — None on file — —
41
EA
Singapore, Singapore
63.0 — — None on file — —
42
IP
Ahmedabad, India
62.3 68.9 3 insp · 5 GMP 2025-09-16 · OAI
Warning letter 2026-03-30
— —
43
OB
Hamilton, ON
61.5 — 0 insp · 2 GMP None on file — —
44
GF
Alameda, CA and South San Francisco
61.5 — — None on file Available —
45
CL
South San Francisco, CA
Hiring · 1 open role
Platform provider
59.0 — — None on file Available —
46
MS
Princeton, NJ
59.0 — — None on file — —
47
OR
London, United Kingdom
Platform provider
59.0 — — None on file — —
48
CC
Toronto, ON, Canada
Academic / national centre
59.0 — — None on file — —
49
MX
Gaithersburg, MD
Platform provider
59.0 — — None on file — —
50
CP
Stevenage, United Kingdom
Academic / national centre
59.0 — — None on file — —
51
C3
Houston, TX
Academic / national centre
59.0 — — None on file — —
52
EX
La Rochelle, France
Hiring · 3 open roles
59.0 — — None on file — —
53
CZ
Cologne, Germany
59.0 — — None on file — —
54
AS
Lake Nona, FL
Hiring · 8 open roles
59.0 — — None on file — —
55
AP
Milpitas, CA
59.0 — — None on file — —
56
CTP
Melbourne, Australia
59.0 — — None on file — —
57
SS
Bloomington, IN
59.0 — — None on file — —
58
PO
San Diego, CA
Hiring · 3 open roles
Also makes its own products
58.7 — — None on file — 6 programs
59
TG
Rancho Cordova, CA
Platform provider
57.8 — — None on file — 1 program
60
KC
Gainesville, FL · Research Triangle Park, NC
Hiring · 8 open roles
56.5 — — None on file — —
61
CX
Freiburg, DE
Reagent supplier
56.5 — — None on file — —
62
GC
Yongin, KR
56.5 — — None on file — —
63
CH
56.5 — — None on file — —
How we score CDMOs →

What to evaluate in a Cell Therapy CDMO

Autologous vs allogeneic
Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.
Vector & raw materials
Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.
Closed-system & cleanrooms
Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.
Cold chain & logistics
Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.

Autologous vs allogeneic — which cell therapy CDMOs handle each?

Autologous and allogeneic cell therapy manufacturing are structurally different: autologous is per-patient batching with chain-of-identity constraints and tight vein-to-vein delivery windows; allogeneic runs larger batch sizes from master cell banks without patient-specific logistics. Most cell therapy CDMOs specialize in one paradigm and only some run both. The modality tags shown on each CDMO profile flag which paradigms a manufacturer supports. Sponsors weighing a CDMO should confirm not just paradigm coverage but the specific unit-of-manufacture — some CDMOs count individual patient batches as one program, others count campaign runs, which changes what "capacity" means.

Which cell therapy CDMOs have commercial approvals?

Commercial cell therapy manufacturing — supporting a marketed product like an approved CAR-T, TCR, or MSC therapy — is a much narrower field than clinical manufacturing. The commercial-scale cell therapy filter surfaces CDMOs with top-quartile Signal Score or broad ClinicalTrials.gov footprint. Sponsors moving a program from clinical to commercial should look for CDMOs whose FDA inspection record specifically covers cell therapy operations — GMP compliance across other modalities does not transfer automatically to cell therapy manufacturing.

How do vein-to-vein timelines vary across cell therapy CDMOs?

Vein-to-vein — the elapsed time from patient apheresis to infusion of manufactured product — is the operational metric that most defines an autologous cell therapy CDMO. Public disclosures are inconsistent, but the two-week target that commercial CAR-T programs operate against is a common floor. CDMO Signal does not publish per-site vein-to-vein numbers directly (published data is unreliable), but the FDA inspection classifications shown in the ranked table reflect batch reliability, which is the underlying process-control property that drives timeline consistency. Sponsors should ask CDMOs for their site-specific benchmarked turnaround as part of due diligence.

How CDMO Signal computes the cell therapy ranking

The cell therapy Signal Score is the platform's standard four-pillar composite. Quality Compliance (35%) leans on FDA inspection classifications (NAI, VAI, OAI), Warning Letter history, and EMA/MHRA GMP certificate density. Operations (25%) reflects ClinicalTrials.gov sponsor and program footprint — for cell therapy this pillar disproportionately captures signal, since clinical activity closely tracks real cell-manufacturing depth. Financial Stability (20%) draws on public/private status and parent-company backing. Capacity Intelligence (20%) counts the manufacturing sites and modalities listed on the profile; job postings are not a score input. Press announcements and SEC filings are shown on profiles as company signals and do not change any score. Full weightings at cdmosignal.com/methodology.

Cell Therapy CDMOs — Frequently Asked Questions

Who are the top Cell Therapy CDMOs?
Among Cell Therapy manufacturers with a fully evidenced Signal Score (all four pillars and at least one ClinicalTrials.gov match), the highest are Bristol Myers Squibb (CGT Mfg), City of Hope (T Cell Manufacturing), Takeda. The table above is the full list. CDMOs cannot pay to change a score.
How many Cell Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 17 Cell Therapy CDMOs with FDA inspection records and 118 EMA/MHRA GMP certificates across the group.
What should I look for in a cell therapy CDMO?
Match the CDMO to your model: autologous needs chain-of-identity and fast turnaround; allogeneic needs scalable batch processing. Confirm vector sourcing, closed-system processing, cold-chain logistics, and a clean FDA and EMA/MHRA record.
Do cell therapy CDMOs make their own viral vectors?
Some do in-house; others coordinate an external vector supplier. In-house vector can shorten timelines and simplify supply, but a strong external partner is common. Check each profile's modality coverage above.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Save this Cell Therapy shortlist
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.
Related modalities
Lentiviral Vector CDMOs CAR-T CDMOs Gene Editing CDMOs
Other Modalities
AAV CAR-T Lentiviral mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector